- Home
- LANV vs GBIO Comparison
LANV vs GBIO Comparison
Compare LANV & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- GBIO
- Stock Information
- Founded
- LANV 2015
- GBIO 2016
- Country
- LANV China
- GBIO United States
- Employees
- LANV N/A
- GBIO N/A
- Industry
- LANV Blank Checks
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- GBIO Health Care
- Exchange
- LANV Nasdaq
- GBIO Nasdaq
- Market Cap
- LANV 173.2M
- GBIO 145.5M
- IPO Year
- LANV N/A
- GBIO 2020
- Fundamental
- Price
- LANV $1.75
- GBIO $2.22
- Analyst Decision
- LANV
- GBIO Buy
- Analyst Count
- LANV 0
- GBIO 4
- Target Price
- LANV N/A
- GBIO $7.50
- AVG Volume (30 Days)
- LANV 80.6K
- GBIO 66.5K
- Earning Date
- LANV 08-26-2024
- GBIO 08-07-2024
- Dividend Yield
- LANV N/A
- GBIO N/A
- EPS Growth
- LANV N/A
- GBIO N/A
- EPS
- LANV N/A
- GBIO N/A
- Revenue
- LANV $409,961,427.00
- GBIO $13,174,000.00
- Revenue This Year
- LANV N/A
- GBIO $99.36
- Revenue Next Year
- LANV $76.77
- GBIO N/A
- P/E Ratio
- LANV N/A
- GBIO N/A
- Revenue Growth
- LANV N/A
- GBIO 1397.05
- 52 Week Low
- LANV $0.91
- GBIO $0.86
- 52 Week High
- LANV $4.70
- GBIO $4.83
- Technical
- Relative Strength Index (RSI)
- LANV 60.60
- GBIO 39.06
- Support Level
- LANV $1.66
- GBIO $2.16
- Resistance Level
- LANV $1.88
- GBIO $2.49
- Average True Range (ATR)
- LANV 0.18
- GBIO 0.21
- MACD
- LANV 0.03
- GBIO -0.03
- Stochastic Oscillator
- LANV 64.29
- GBIO 3.85
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.